These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 29557414

  • 21. [Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].
    Wang W, Shi LP, Shi L, Xu L.
    Zhonghua Nei Ke Za Zhi; 2018 Feb 01; 57(2):101-106. PubMed ID: 29397594
    [Abstract] [Full Text] [Related]

  • 22. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD, Mundhofir FE, Kasno, Sudijanto E, Darmono, Daldiyono, Djokomoeljanto R, Faradz SM.
    Acta Med Indones; 2015 Jan 01; 47(1):16-23. PubMed ID: 25948763
    [Abstract] [Full Text] [Related]

  • 23. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial.
    Sepideh A, Karim P, Hossein A, Leila R, Hamdollah M, Mohammad E G, Mojtaba S, Mohammad S, Ghader G, Seyed Moayed A.
    J Am Coll Nutr; 2016 Aug 01; 35(6):500-505. PubMed ID: 26430826
    [Abstract] [Full Text] [Related]

  • 24. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A.
    Diabetes Care; 2018 Aug 01; 41(8):1801-1808. PubMed ID: 29895557
    [Abstract] [Full Text] [Related]

  • 25. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
    Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A.
    J Gastroenterol Hepatol; 2016 May 01; 31(5):936-44. PubMed ID: 26667191
    [Abstract] [Full Text] [Related]

  • 26. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.
    Cochrane Database Syst Rev; 2013 Dec 27; (12):CD008623. PubMed ID: 24374462
    [Abstract] [Full Text] [Related]

  • 27. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG.
    BMC Med; 2016 Jun 29; 14():92. PubMed ID: 27353492
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E, NASH CRN.
    Gastroenterology; 2016 Dec 29; 151(6):1141-1154.e9. PubMed ID: 27569726
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Association between thymosin beta4 and non-alcoholic fatty liver disease.
    Jiang Y, Zhang Y, Ma CH, Zhang ZG, Li M, Ji YL, Qi FX.
    Rev Esp Enferm Dig; 2019 Apr 29; 111(4):308-313. PubMed ID: 30896961
    [Abstract] [Full Text] [Related]

  • 32. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S.
    Nutr Clin Pract; 2013 Feb 29; 28(1):101-11. PubMed ID: 23042833
    [Abstract] [Full Text] [Related]

  • 33. [Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease].
    Liu YT, Li YQ, Wang YZ.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Dec 20; 24(12):921-926. PubMed ID: 28073414
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention.
    Kobyliak N, Falalyeyeva T, Virchenko O, Mykhalchyshyn G, Bodnar P, Spivak M, Yankovsky D, Beregova T, Ostapchenko L.
    BMC Gastroenterol; 2016 Mar 15; 16():34. PubMed ID: 26976285
    [Abstract] [Full Text] [Related]

  • 36. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD.
    Br J Nutr; 2018 Jul 15; 120(2):164-175. PubMed ID: 29947322
    [Abstract] [Full Text] [Related]

  • 37. [Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease].
    Mykhal'chyshyn HP, Bodnar PM, Kobyliak NM.
    Lik Sprava; 2013 Mar 15; (2):56-62. PubMed ID: 24605611
    [Abstract] [Full Text] [Related]

  • 38. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.
    Sangouni AA, Mohammad Hosseini Azar MR, Alizadeh M.
    Br J Nutr; 2020 Aug 28; 124(4):450-456. PubMed ID: 32312333
    [Abstract] [Full Text] [Related]

  • 39. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial.
    Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W.
    J Dig Dis; 2017 Dec 28; 18(12):698-703. PubMed ID: 29148175
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Kim KJ, Han KH.
    Dig Dis Sci; 2017 Aug 28; 62(8):2150-2158. PubMed ID: 28523578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.